Mark Chilvers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8148731/publications.pdf

Version: 2024-02-01

30 papers	1,892 citations	471509 17 h-index	454955 30 g-index
34 all docs	34 docs citations	34 times ranked	2177 citing authors

#	Article	IF	Citations
1	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children â‰¥Â6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis, 2022, 21, 675-683.	0.7	10
2	Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. Npj Genomic Medicine, 2022, 7, 28.	3.8	7
3	Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 57-60.	0.7	4
4	Long-term safety of lumacaftorâ€“ivacaftor in children aged 2â€“5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 977-988.	10.7	28
5	Cystic fibrosisâ€“related diabetes onset can be predicted using biomarkers measured at birth. Genetics in Medicine, 2021, 23, 927-933.	2.4	17
6	Performance of a Three-Tier (IRT-DNA-IRT) Cystic Fibrosis Screening Algorithm in British Columbia. International Journal of Neonatal Screening, 2020, 6, 46.	3.2	5
7	Matrix-assisted laser desorption/ionization time-of-flight MS for the accurate identification of Burkholderia cepacia complex and Burkholderia gladioli in the clinical microbiology laboratory. Journal of Medical Microbiology, 2020, 69, 1105-1113.	1.8	8
8	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11â€¯years with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 708-713.	0.7	44
9	Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 802-809.	10.7	89
10	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2â€“5â€¯years (KLIMB). Journal of Cystic Fibrosis, 2019, 18, 838-843.	0.7	94
11	Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population. Annals of the American Thoracic Society, 2018, 15, 827-836.	3.2	13
12	Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis. Human Vaccines and Immunotherapeutics, 2017, 13, 1254-1260.	3.3	6
13	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6â€“11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2017, 5, 557-567.	10.7	243
14	Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. Vaccine, 2017, 35, 5019-5026.	3.8	1
15	Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings. Open Forum Infectious Diseases, 2016, 3, ofw187.	0.9	3
16	Dornase alfa for cystic fibrosis. The Cochrane Library, 2016, 4, CD001127.	2.8	91
17	Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 755-762.	0.7	62
18	Casting a look at pediatric plastic bronchitis. International Journal of Pediatric Otorhinolaryngology, 2015, 79, 1658-1661.	1.0	14

#	Article	IF	Citations
19	Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 262-266.	0.7	45
20	Cystic fibrosis adolescent transition care in Canada: A snapshot of current practice. Paediatrics and Child Health, 2012, 17, 553-556.	0.6	11
21	Case 1: Chronic cough in a Vietnamese adolescent: Should we be sweating?. Paediatrics and Child Health, 2011, 16, 465-466.	0.6	1
22	Longâ€term comparative trial of two different physiotherapy techniques; postural drainage with percussion and autogenic drainage, in the treatment of cystic fibrosis. Pediatric Pulmonology, 2010, 45, 1064-1069.	2.0	38
23	Diagnostic Testing of Patients Suspected of Primary Ciliary Dyskinesia. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 307-314.	5.6	116
24	Pleuropulmonary complications of PVLâ€positive Staphylococcus aureus infection in children. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 1372-1375.	1.5	20
25	Diagnosing primary ciliary dyskinesia. Thorax, 2007, 62, 656-657.	5.6	64
26	Ciliary beat pattern is associated with specific ultrastructural defects in primary ciliary dyskinesia. Journal of Allergy and Clinical Immunology, 2003, 112, 518-524.	2.9	282
27	Functional analysis of cilia and ciliated epithelial ultrastructure in healthy children and young adults. Thorax, 2003, 58, 333-338.	5.6	122
28	The effects of coronavirus on human nasal ciliated respiratory epithelium. European Respiratory Journal, 2001, 18, 965-970.	6.7	159
29	Analysis of ciliary beat pattern and beat frequency using digital high speed imaging: comparison with the photomultiplier and photodiode methods. Thorax, 2000, 55, 314-317.	5.6	209
30	Local mucociliary defence mechanisms. Paediatric Respiratory Reviews, 2000, 1, 27-34.	1.8	86